Skip to Main Content
Skip Nav Destination

Are you up to speed on latest asthma management guidelines?

October 4, 2021
Topics:

Editor's note: For more coverage of the 2021 AAP National Conference & Exhibition, visit https://www.aappublications.org/news/2021/08/18/nationalconference2021.

Theresa W. Guilbert, M.D., M.S., FAAP, will present “Asthma 101: Review of Updated NHLBI Guidelines” (L4401) from 2:30-3:30 p.m. CDT Monday, Oct. 11.

Dr. Guilbert is director of the Asthma Center, Division of Pulmonology Medicine, at Cincinnati Children's Hospital Medical Center. She also is a member of the AAP Section on Pediatric Pulmonology and Sleep Medicine Executive Committee.

In the following Q&A, Dr. Guilbert summarizes the burden of asthma, what she plans to discuss and why this session is important for pediatricians.

Q: How did you get interested in treating children with asthma?

A: During my pulmonary fellowship, I enjoyed caring for children with severe asthma and was interested in clinical research in this area.  My first position was at the University of Arizona, and I got involved in severe asthma-related research studies there.

Q: How many children in the U.S. have asthma?

A: There are 5.1 million children under the age of 18 with asthma. It is the leading chronic disease in children.

Q: What are the key things you will be covering during the session?

A: Five topics that were updated in the National Heart, Lung, and Blood Institute (NHLBI) 2020 Focused Updates to the Asthma Management Guidelines that are relevant to children will be discussed, including:

  • adjustable medication dosing in recurrent wheezing and asthma,
  • long-acting anti-muscarinic agents in asthma management as add-on to inhaled corticosteroids,
  • fractional exhaled nitric oxide in diagnosis, medication selection and monitoring of treatment response in asthma,
  • remediation of indoor allergens in asthma management, and
  • immunotherapy and the management of asthma.

Q: What is the take-home message of the session?

A: There is evidence-based support for use of intermittent inhaled corticosteroid therapy and single maintenance and reliever therapy (SMART) in the management of childhood asthma.

Close Modal

or Create an Account

Close Modal
Close Modal